Showing session: reset
Can the Challenge of NSCLC Resistance Be MET or Will We Not MEK It?
- Sort by:
- Browse by:
- Permission not
granted for presentation
Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations
Shun Lu
Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
- Free
- slides video
- audio + slides
- All slides included
TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
Lecia Sequist
Massachusetts General Hospital, Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study
Suresh S Ramalingam
Emory Univ. Winship Cancer Inst., Atlanta, GA, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Roy S Herbst
Yale Cancer Ctr., New Haven, CT, United States